Recruiting
Phase 1
Phase 2

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Sponsor:

Jazz Pharmaceuticals

Code:

NCT05734066

Conditions

Refractory Ewing Sarcoma

Relapsed Ewing Sarcoma

Ewing Sarcoma

Eligibility Criteria

Sex: All

Age: 2 - 30

Healthy Volunteers: Not accepted

Interventions

Lurbinectedin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information